EPS for Johnson & Johnson (JNJ) Expected At $1.79

September 17, 2017 - By test

 EPS for Johnson & Johnson (JNJ) Expected At $1.79
Investors sentiment increased to 0.94 in Q4 2016. Its up 0.12, from 0.82 in 2016Q3. It improved, as 63 investors sold Johnson & Johnson shares while 834 reduced holdings. 114 funds opened positions while 731 raised stakes. 1.72 billion shares or 0.88% more from 1.71 billion shares in 2016Q3 were reported.
Credit Agricole S A has 1.14% invested in Johnson & Johnson (NYSE:JNJ) for 3.08M shares. Inv Partners Ltd Oh Adv reported 16,962 shares. Elm Advisors has 5,473 shares. 493,076 are held by Armstrong Henry H Assoc. Berkshire Hathaway Inc has 327,100 shares for 0.03% of their portfolio. Viking Fund Mngmt Lc holds 0.47% or 32,000 shares. Riverpoint Mngmt Ltd accumulated 153,592 shares. Reilly Herbert Faulkner Iii holds 37,482 shares or 3.05% of its portfolio. Moon Cap Management Ltd Liability Corporation reported 6,477 shares. Veritas Management Llp has invested 0.07% in Johnson & Johnson (NYSE:JNJ). Security Natl Bank Of So Dak holds 2.25% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 16,005 shares. First Fincl Bank Of Omaha accumulated 48,729 shares. Lawson Kroeker Investment Management Inc Ne has invested 3.59% in Johnson & Johnson (NYSE:JNJ). Nj State Employees Deferred Compensation Plan holds 1.14% or 50,000 shares. Foothills Asset Ltd invested 1.35% of its portfolio in Johnson & Johnson (NYSE:JNJ).

Investors wait Johnson & Johnson (NYSE:JNJ) to report on October, 17 before the open. its quarterly earnings Wall Street analysts expect $1.79 earnings per share, up $0.11 or 6.55 % from last year’s $1.68 same quarter earnings. This translates into $4.80B profit for JNJ giving the stock a 18.78 P/E. This is assuming the current $1.79 EPS is accurate. Johnson & Johnson’s Wall Street analysts see -2.19 % negative EPS growth, taking into account the $1.83 EPS reproted in the previous quarter, The stock increased 0.13% or $0.18 on September 15, reaching $134.45. About 15.52M shares traded or 199.04% up from the average. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since September 17, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 22 analysts covering Johnson & Johnson (NYSE:JNJ), 10 have Buy rating, 4 Sell and 8 Hold. Therefore 45% are positive. Johnson & Johnson had 64 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Johnson & Johnson (NYSE:JNJ) earned “Neutral” rating by Goldman Sachs on Wednesday, April 20. The firm earned “Buy” rating on Monday, July 10 by BMO Capital Markets. Barclays Capital upgraded the stock to “Overweight” rating in Tuesday, December 1 report. The stock of Johnson & Johnson (NYSE:JNJ) earned “Hold” rating by Jefferies on Thursday, August 4. The rating was maintained by Jefferies with “Hold” on Friday, July 14. On Wednesday, January 25 the stock rating was maintained by RBC Capital Markets with “Outperform”. Jefferies maintained Johnson & Johnson (NYSE:JNJ) on Tuesday, June 14 with “Hold” rating. The firm has “Buy” rating given on Wednesday, October 19 by UBS. The stock of Johnson & Johnson (NYSE:JNJ) has “Overweight” rating given on Monday, May 15 by JP Morgan. Alembic downgraded Johnson & Johnson (NYSE:JNJ) on Friday, July 21 to “Underweight” rating.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The company has market cap of $360.86 billion. It operates through three divisions: Consumer, Pharmaceutical and Medical Devices. It has a 22.73 P/E ratio. The Company’s primary focus is products related to human health and well-being.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Achillion Is Crushed As Johnson & Johnson Heads For The Exit” on September 14, 2017, also Realmoney.Thestreet.com with their article: “Johnson & Johnson Is Getting Ready for Another Upside Breakout” published on September 15, 2017, Cnbc.com published: “Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends” on September 11, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson: (Some) More Room To Go” published on September 09, 2017 as well as Seekingalpha.com‘s news article titled: “Johnson & Johnson – This Is A Dividend Machine” with publication date: September 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.